Concurrent palliative radiation with pembrolizumab for platinum-refractory urothelial carcinoma is associated with improved overall survival

BACKGROUND AND PURPOSE: Pembrolizumab has now become a standard of care in metastatic urothelial carcinoma (mUC), although the treatment effect of the drug substantially differs among individuals. Emerging evidence suggests that radiotherapy exerts a synergistic effect with PD-1 blockade. We sought...

Descripción completa

Detalles Bibliográficos
Autores principales: Nakamori, Keita, Yamazaki, Shogo, Komura, Kazumasa, Fukuokaya, Wataru, Adachi, Takahiro, Hirasawa, Yosuke, Hashimoto, Takeshi, Yoshizawa, Atsuhiko, Ohno, Takaya, Yano, Yusuke, Nishimura, Kazuki, Tokushige, Satoshi, Uchimoto, Taizo, Yamamoto, Shutaro, Iwatani, Kosuke, Urabe, Fumihiko, Mori, Keiichiro, Yanagisawa, Takafumi, Tsuduki, Shunsuke, Takahara, Kiyoshi, Inamoto, Teruo, Miki, Jun, Kimura, Takahiro, Ohno, Yoshio, Shiroki, Ryoichi, Azuma, Haruhito
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9762181/
https://www.ncbi.nlm.nih.gov/pubmed/36545361
http://dx.doi.org/10.1016/j.ctro.2022.12.001

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9762181/
https://www.ncbi.nlm.nih.gov/pubmed/36545361
http://dx.doi.org/10.1016/j.ctro.2022.12.001

Ejemplares similares